Oct. 10, 2025
| Today’s news and insights for biopharma leaders
The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.
|
The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for chronic skin hives.
|
News roundup
The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, Ferring announced layoffs and Sanofi touted a radiopharmaceutical drug.
|
The secret to on-time trials? Engaging recruitment partners early.
|
UPDATED
Bristol’s buyout of Orbital and Novo’s acquisition of Akero both center on areas of drug research — ‘in vivo’ cell therapies and MASH medicines — that have been the focus of several other acquisitions this year.
|
The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.
|
|
Pharma leaders investing millions in events often lack visibility into cross-meeting engagement patterns that could maximize ROI. Explore a data approach that turns attendee insights into advantages in this playbook.
|
|
From Our Library
Playbook
Custom content for WCG
|
Webinar - on demand
Custom content for Endava
|
Infographic
Custom content for Woven Health Collective
|
Trendline
Supported by ELEGEN
|
| 
